Freenome is known for seeing what humans cannot see. By decoding cell-free biomarker patterns of once-unthinkable complexity, Freenome’s blood tests are powered by its multi-omics platform and designed to detect cancer with the help of machine learning and molecular biology at its earliest stages to help clinicians optimize treatments and the next generation of precision therapies.
By training on thousands of cancer-positive blood samples, Freenome’s multi-omics platform learns which biomarker patterns signify cancer’s type and effective treatment pathways. Training on healthy samples helps experts to establish what a normal composition of cell-free biomarkers should look like. This unique concept of Freenome makes the company stand out among all.
Freenome’s multiomics platform detects key biological signals from a routine blood draw. The platform integrates assays for cell-free DNA, methylation, and proteins with advanced computational biology and machine learning techniques to understand additive signatures for early cancer detection.
This strategy incorporates a multidimensional view of both tumor- and non-tumor-derived (e.g. immune) signatures that enable the early detection of cancer, instead of relying only on tumor-derived markers, which may miss the early signs of cancer.
Panorama des menaces cyber en 2025 : Implications pour les entreprises françaises à l'ère de…
Introduction L'adoption croissante des technologies d'intelligence artificielle dans le secteur de la santé offre des…
La révolution IA dans le secteur de la santé : nouveaux défis de cybersécurité La…
En tant que PME sous-traitante de grands groupes, vous connaissez trop bien ce scénario :…
Votre entreprise vient de subir une cyberattaque. Dans le feu de l'action, vous avez mobilisé…
"Mais concrètement, à quoi sert un scanner de vulnérabilité pour une entreprise comme la nôtre?"…
This website uses cookies.